Press releases
2026
At the DDF Summit 2026 in Berlin, Disruptive Pharma presented an award-winning poster on Formulite®, our bioavailability enhancement platform for poorly soluble oral drugs. The poster, which won the 2026 Poster Competition, summarizes technical and clinical validation data, including improved dissolution, higher drug loading, bioavailability...
7 May, 2026
Case study: Fast-track formulation development
During a visit to a potential partner, the
objective was to rapidly assess the feasibility of formulating a
poorly soluble compound using Formulite® — and generate material
for downstream development without entering a lengthy formulation
program. Approach focused, on-site development sprint was conducted over two days,
combining feasibility...
We are pleased to welcome Ellen Brunzell to Disruptive Pharma. Ellen is a licensed pharmacist and recently completed her PhD in pharmaceutical physical chemistry at Uppsala University. Her research has focused on drug substances, formulation-relevant interactions and peptide aggregation, bringing valuable expertise to our work in pharmaceutical...
31 March, 2026
Guard Therapeutics provides update on strategic review
Guard Therapeutics International AB (publ) (“Guard Therapeutics” or the “Company”) hereby provides an update regarding the strategic review that was announced in December 2025.
Guard Therapeutics International AB (publ) (“Guard Therapeutics” or the “Company”) hereby provides a status update regarding the strategic review that the Company announced through a press release on 4 December 2025. The review, which includes an exploration of potential strategic alternatives, including the identification of potential...